Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Evaluation of QuantiFERON SARS-CoV-2 interferon-γrelease assay following SARS-CoV-2 infection and vaccination
Clinical and Experimental Immunology, Volume 212, No. 3, Year 2023
Notification
URL copied to clipboard!
Description
T cells are important in preventing severe disease from SARS-CoV-2, but scalable and field-adaptable alternatives to expert T-cell assays are needed. The interferon-gamma release assay QuantiFERON platform was developed to detect T-cell responses to SARS-CoV-2 from whole blood with relatively basic equipment and flexibility of processing timelines. Forty-eight participants with different infection and vaccination backgrounds were recruited. Whole blood samples were analysed using the QuantiFERON SARS-CoV-2 assay in parallel with the well-established 'Protective Immunity from T Cells in Healthcare workers' (PITCH) ELISpot, which can evaluate spike-specific T-cell responses. The primary aims of this cross-sectional observational cohort study were to establish if the QuantiFERON SARS-Co-V-2 assay could discern differences between specified groups and to assess the sensitivity of the assay compared with the PITCH ELISpot. The QuantiFERON SARS-CoV-2 distinguished acutely infected individuals (12-21 days post positive PCR) from naïve individuals (P < 0.0001) with 100% sensitivity and specificity for SARS-CoV-2 T cells, whilst the PITCH ELISpot had reduced sensitivity (62.5%) for the acute infection group. Sensitivity with QuantiFERON for previous infection was 12.5% (172-444 days post positive test) and was inferior to the PITCH ELISpot (75%). Although the QuantiFERON assay could discern differences between unvaccinated and vaccinated individuals (55-166 days since second vaccination), the latter also had reduced sensitivity (44.4%) compared to the PITCH ELISpot (66.6%). The QuantiFERON SARS-CoV-2 assay showed potential as a T- cell evaluation tool soon after SARS-CoV-2 infection but has lower sensitivity for use in reliable evaluation of vaccination or more distant infection. © 2023 The Author(s). Published by Oxford University Press on behalf of the British Society for Immunology.
Authors & Co-Authors
Johnson, Síle Ann
United Kingdom, Oxford
University of Oxford
United Kingdom, Derby
University Hospitals of Derby and Burton Nhs Foundation Trust
Phillips, Eloise
United Kingdom, Oxford
University of Oxford
Adele, Sandra
United Kingdom, Oxford
University of Oxford
Thailand, Nakhon Pathom
Mahidol University
Longet, Stéphanie
United Kingdom, Oxford
The Wellcome Centre for Human Genetics
United Kingdom, Oxford
University of Oxford
Malone, Tom
United Kingdom, Oxford
University of Oxford
Mason, Chris J.B.
United Kingdom, Oxford
University of Oxford
Stafford, Lizzie
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
United Kingdom, Oxford
University of Oxford
Jämsén, Anni
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
United Kingdom, Oxford
University of Oxford
Gardiner, Siobhan
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
United Kingdom, Oxford
University of Oxford
Deeks, Alexandra S.
United Kingdom, Oxford
University of Oxford
White, Jemima
United Kingdom, Oxford
University of Oxford
Skelly, Dónal Thomas
United Kingdom, Oxford
University of Oxford
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
Jeffery, Katie J.M.
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
United Kingdom, Oxford
University of Oxford
Conlon, Christopher P.
United Kingdom, Oxford
University of Oxford
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
Goulder, Philip Jeremy Renshaw
United Kingdom, Oxford
University of Oxford Medical Sciences Division
Carroll, Miles W.
United Kingdom, Oxford
The Wellcome Centre for Human Genetics
United Kingdom, Oxford
University of Oxford
Barnes, Eleanor J.
United Kingdom, Oxford
University of Oxford
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
United Kingdom, Oxford
Nihr Oxford Biomedical Research Centre
Klenerman, Paul
United Kingdom, Oxford
University of Oxford
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
United Kingdom, Oxford
Nihr Oxford Biomedical Research Centre
Dunachie, Susanna J.
United Kingdom, Oxford
University of Oxford
Thailand, Nakhon Pathom
Mahidol University
United Kingdom, Oxford
Oxford University Hospitals Nhs Foundation Trust
Statistics
Citations: 4
Authors: 19
Affiliations: 8
Identifiers
Doi:
10.1093/cei/uxad027
ISSN:
00099104
Research Areas
Health System And Policy
Study Design
Cross Sectional Study
Cohort Study
Study Approach
Quantitative